Promising combo targets tough lung cancer
NCT ID NCT07548060
First seen Apr 24, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and furmonertinib, in 25 adults with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has worsened after standard treatments. The goal is to see if the combo can shrink tumors or slow disease progression. Participants must have stage IIIB/IV cancer and meet specific health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.